Acquisition by Do Cuong V of 104502 shares of Biovie at 1.9 subject to Rule 16b-3
BIVI Stock | USD 1.67 0.02 1.21% |
Under 65% of Biovie's investor base is looking to short. The analysis of the overall investor sentiment regarding Biovie Inc suggests that many traders are alarmed. Biovie's investing sentiment shows overall attitude of investors towards Biovie Inc.
Biovie |
Filed transaction by Biovie Inc Director, Officer: President & Ceo. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Biovie's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Biovie's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Biovie Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Biovie can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biovie Fundamental Analysis
We analyze Biovie's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biovie using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biovie based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Biovie is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Biovie Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biovie stock to make a market-neutral strategy. Peer analysis of Biovie could also be used in its relative valuation, which is a method of valuing Biovie by comparing valuation metrics with similar companies.
Peers
Biovie Related Equities
XFOR | X4 Pharmaceuticals | 6.06 | ||||
AMLX | Amylyx Pharmaceuticals | 3.99 | ||||
MREO | Mereo BioPharma | 2.73 | ||||
INZY | Inozyme Pharma | 1.37 | ||||
HOOK | Hookipa Pharma | 2.00 | ||||
DAWN | Day One | 3.81 | ||||
ABOS | Acumen Pharmaceuticals | 3.85 | ||||
TERN | Terns Pharmaceuticals | 3.88 | ||||
ELDN | Eledon Pharmaceuticals | 5.44 |
Complementary Tools for Biovie Stock analysis
When running Biovie's price analysis, check to measure Biovie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biovie is operating at the current time. Most of Biovie's value examination focuses on studying past and present price action to predict the probability of Biovie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biovie's price. Additionally, you may evaluate how the addition of Biovie to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |